The Federal Trade Commission’s interim report on the findings of its two-year investigation of pharmacy benefit managers flags “exclusionary rebating” as warranting further scrutiny as media reports surface that the commission may sue the three largest PBMs over their insulin contracting practices.
“Consistent with our commitment to share information with the public and policymakers as quickly as possible, we … confirm several...







